Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is rated as an Elite provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy.

Yannis M. Paulus, M.D., F.A.C.S., is the Jonas Fridenwald Professor in Ophthalmology, an associate professor in the Johns Hopkins University Department of Ophthalmology and Department of Biomedical Engineering, and a vitreoretinal surgeon at the Wilmer Eye Institute, Johns Hopkins Medicine’s East Baltimore and Columbia locations. Dr. Paulus served as a surgical retina specialist and director of a research laboratory at the University of Michigan Kellogg Eye Center for almost 10 years, where he developed novel imaging systems, lasers and long-lasting therapies and nanotechnologies to allow physicians to determine cellular markers of disease, enabling early diagnosis, improved treatment monitoring and more individualized, personalized precision medicine tailored to each patient’s needs. After earning his bachelor’s degree in chemistry and physics from Harvard University and his medical degree at Stanford University School of Medicine, Dr. Paulus completed an internship at the Sloan-Kettering Cancer Center, a residency in ophthalmology at the Stanford University School of Medicine Byers Eye Institute, and a surgical and medical retina fellowship at Wilmer Eye Institute, Johns Hopkins Medicine. CVhttps://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Paulus_CV%2021225.pdf. Dr. Paulus is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Vitrectomy, and Cataract Removal.

Akrit Sodhi, M.D, Ph.D., is an Associate Professor of Ophthalmology at the Wilmer Eye Institute and holds the Branna and Irving Sisenwein Professorship in Ophthalmology. Dr. Sodhi specializes in the medical and surgical management of complex vitreoretinal diseases. Dr. Sodhi was trained at the University of California at Los Angeles (UCLA), the University of California at Davis, and the National Institutes of Health. After obtaining his M.D. and Ph.D., he interned at Sinai Hospital in Baltimore and completed his Ophthalmology Residency training at the Wilmer Eye Institute at Johns Hopkins in 2008. He then pursued a fellowship in vitreoretinal surgery at Wilmer where he also served as the Assistant Chief of Service (Chief Resident). Dr. Sodhi joined the faculty of the Retina Division at Wilmer in 2010. His research interests, currently sponsored by grants from the National Eye Institute, include the examination of the role of hypoxia inducible factor (HIF) and HIF-regulated genes in ocular diseases, including diabetic eye disease, age-related macular degeneration, sickle cell retinopathy, retinal vein occlusions, and uveal melanoma. Dr. Sodhi's lab has identified novel therapeutic targets for the treatment of these vision-threatening diseases. Dr. Sodhi is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, and Late-Onset Retinal Degeneration.

Sharon D. Solomon, M.D., is the Katharine M. Graham Professor of Ophthalmology at the Wilmer Eye Institute. A retina specialist and ophthalmologist, Dr. Solomon's clinical expertise includes medical and surgical treatment of age-related macular degeneration, diabetic retinopathy, epiretinal membranes, macular holes, and retinal tears and detachment. Dr. Solomon has a large national and international referral practice at Wilmer. Dr. Solomon has served as principal investigator at Wilmer on a number of NIH-sponsored clinical trials. She has numerous publications from her clinical trials involvement. Dr. Solomon received her bachelor's degree in biochemistry from Harvard University and her medical degree from the University of California, San Francisco. After her internship at Stanford, she returned to UCSF for her residency in ophthalmology. Dr. Solomon completed her surgical retina fellowship at the Wilmer Eye Institute prior to joining the faculty. Dr. Solomon is a member of the prestigious Miller-Coulson Academy of Clinical Excellence at Johns Hopkins. Dr. Solomon is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. Her top areas of expertise are Retinal Vein Occlusion, Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Gyrate Atrophy of the Choroid and Retina, and Vitrectomy.

Joseph Harlan is an Ophthalmologist in Lutherville, Maryland. Dr. Harlan is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Diabetic Retinopathy, Late-Onset Retinal Degeneration, Retinal Artery Occlusion, and Age-Related Macular Degeneration (ARMD). Dr. Harlan is currently accepting new patients.

Ingrid Zimmer-Galler is an Ophthalmologist in Frederick, Maryland. Dr. Zimmer-Galler is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. Her top areas of expertise are Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), and Diabetic Retinopathy. Dr. Zimmer-Galler is currently accepting new patients.

Michael Grodin is an Ophthalmologist in Lutherville, Maryland. Dr. Grodin is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, and Retinal Artery Occlusion. Dr. Grodin is currently accepting new patients.

Michael Elman is an Ophthalmologist in Baltimore, Maryland. Dr. Elman is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Diabetic Retinopathy, Retinal Vein Occlusion, and Vitrectomy. Dr. Elman is currently accepting new patients.

Allen Hu is an Ophthalmologist in Cumberland, Maryland. Dr. Hu is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Geographic Atrophy, Diabetic Retinopathy, and Vitrectomy.

Gary Miller is an Ophthalmologist in Oakland, Maryland. Dr. Miller is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Retinal Vein Occlusion, and Diabetic Retinopathy. Dr. Miller is currently accepting new patients.

David Warrow is an Ophthalmologist in Hagerstown, Maryland. Dr. Warrow is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinal Artery Occlusion, Retinal Detachment, and Vitrectomy. Dr. Warrow is currently accepting new patients.

Adam Gerstenblith is an Ophthalmologist in Hagerstown, Maryland. Dr. Gerstenblith is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Geographic Atrophy, Diabetic Retinopathy, and Vitrectomy. Dr. Gerstenblith is currently accepting new patients.

Adam Wenick is an Ophthalmologist in Hagerstown, Maryland. Dr. Wenick is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Retinal Vein Occlusion, Retinal Detachment, and Vitrectomy. Dr. Wenick is currently accepting new patients.

Mary Aronow is an Ophthalmologist in Mount Airy, Maryland. Dr. Aronow is rated as a Distinguished provider by MediFind in the treatment of Retinal Vein Occlusion. Her top areas of expertise are Melanoma of the Eye, Choroid Plexus Carcinoma, Metastatic Uveal Melanoma, Uveal Melanoma, and Vitrectomy. Dr. Aronow is currently accepting new patients.

Dr. Susan Bressler is the Julia G. Levy, Ph.D. Professor of Ophthalmology at the Wilmer Eye Institute. She is an ophthalmologist and has subspecialty training in medical retinal disorders, vitreoretinal disease, and retinal surgery. Her main research interest has been collaborative efforts in clinical trials - serving as principal investigator of an image reading center that has served as a central unit for many clinical trials and epidemiologic investigations, as Vice Chair of the Diabetic Retinopathy Clinical Research Network and as principal investigator of a participating clinical center in several major clinical trials. Most studies have specific emphasis on the treatment of both non-neovascular and neovascular age-related macular degeneration and all aspects of diabetic retinopathy. Dr. Bressler has a large national and international referral practice. In addition, she has published 223 peer reviewed articles and 55 book chapters. Editorial Board positions have included American Journal of Ophthalmology, Survey of Ophthalmology, Retina, EyeNet Magazine, Health After 50: The Johns Hopkins Medical Letter and the Wilmer Retina Update. Dr. Bressler is rated as an Experienced provider by MediFind in the treatment of Retinal Vein Occlusion. Her top areas of expertise are Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Diabetic Retinopathy, and Vitrectomy.

Mandeep S. Singh, M.D., Ph.D., is associate professor of ophthalmology and genetic medicine in the Retina Division of the Wilmer Eye Institute and the recipient of the 2023 Andreas C. Dracopoulos Professorship in Ophthalmology. Dr. Singh is a retinal specialist. He is Co-Director of the Genetic Eye Disease (GEDi) Center, and is a principal investigator at the Center for Stem Cells and Ocular Regenerative Medicine (STORM). Dr. Singh completed his medical degree at the National University of Singapore. In 2009, he was elected to the Fellow of the Royal College of Surgeons of Edinburgh. He earned a PhD in ophthalmology from the University of Oxford, United Kingdom, in 2014. He completed fellowships in vitreoretinal diseases and surgery at the Oxford Eye Hospital and Moorfields Eye Hospital, both in the United Kingdom. His clinical expertise includes surgical, medical and genetic conditions of the retina and macula. Dr. Singh is specialty-trained in vitrectomy surgery for retinal detachment, macular holes, macular pucker, epiretinal membrane, proliferative vitreoretinopathy, complex retinal detachments including reoperations, vitreous hemorrhage removal, and other retinal surgeries. He also specializes in age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, and choroidal neovascularization. Dr. Singh sees patients and families with genetic retinal diseases such as retinitis pigmentosa, Usher syndrome, Stargardt disease and macular dystrophies. His research focus is retinal stem cell transplantation. Dr. Singh’s work has been recognized through the Eye Institute–Allergan Research Prize, the Merton College University of Oxford Graduate Prize Scholarship, the Oxford Ophthalmological Congress Founder’s Cup and Medal, the Ruskell Medal, the Johns Hopkins Clinician Scientist Award, and the Bert M. Glaser, MD Award for Innovative Research in Retina. He is a member of the American Academy of Ophthalmology and the Association for Research in Vision and Ophthalmology. He is also a member of the Club Jules Gonin and the Macula Society. CV https://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Singh_CV.pdf. Dr. Singh is rated as an Experienced provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Leber Congenital Amaurosis, Sorsby Fundus Dystrophy, Usher Syndrome Type 2A, and Doyne Honeycomb Retinal Dystrophy.

Mona Kaleem, M.D. is an Associate Professor of Ophthalmology at the Wilmer Eye Institute. She is a fellowship trained glaucoma and cataract surgeon in Bethesda, Maryland. She is broadly trained in the medical and surgical care of glaucoma. Her excellence in patient care, teaching, and research activities resulted in her selection to the American Glaucoma Society. She was also selected by her peers as a Baltimore Magazine “Top Doctor” in 2018, 2019 and 2021. In 2020, Dr. Kaleem was honored with the American Academy of Ophthalmology's Achievement Award. Dr. Kaleem was born and raised in Maryland. She earned her Bachelor’s degree in Economics with double minors in Biology and Chemistry at Smith College prior to entering the Howard University College of Medicine. There, she was a Trustee Scholar and awardee of the Malcolm X Scholarship due to her leadership in community service. She completed her medical training at Mercy Medical Center, Howard University Hospital, and the Cleveland Clinic. She has a strong interest in volunteerism and has participated in medical missions globally and in underserved areas within the United States. Dr. Kaleem is also known for her involvement in grass roots legislative efforts that impact the way that ophthalmology care is delivered and received in the United States. She is one of the hosts of the Diagnosis Glaucoma podcast and co-authored the book Glaucoma: What Every Patient Should Know with Dr. Harry Quigley. CV https://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Kaleem-cv.pdf. Dr. Kaleem is rated as an Experienced provider by MediFind in the treatment of Retinal Vein Occlusion. Her top areas of expertise are Glaucoma, Ocular Hypertension (OHT), Cataract, Vitrectomy, and Trabeculectomy.

Jacob Kanter, M.D., is a cataract and glaucoma surgeon practicing at the Wilmer Eye Institute, Johns Hopkins Medicine. Dr. Kanter is a glaucoma specialist who focuses on the diagnosis, treatment and management of all forms of open angle and angle-closure glaucoma. He performs cataract surgery and glaucoma surgery, including both the latest micro invasive glaucoma surgeries (MIGS) and traditional glaucoma surgeries. He also performs clinic-based procedures including selective laser trabeculoplasty (SLT), YAG laser capsulotomy and laser peripheral iridotomy. Dr. Kanter is involved with several clinical trials investigating the latest glaucoma surgeries. He is also researching the role of home tonometry in glaucoma care, which can uncover intraocular pressure fluctuations outside the office and help elucidate how glaucoma progresses. He has a special interest in improving patient-doctor communication, streamlining patients’ experiences with glaucoma surgery, and medical education. Dr. Kanter is rated as an Experienced provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Glaucoma, Ocular Hypertension (OHT), Pigment-Dispersion Syndrome, Retinal Vein Occlusion, and Trabeculectomy.

Dr. Neil Bressler has been a member of the Wilmer Eye Institute's faculty since 1988 and is the inaugural James P. Gills Professor of Ophthalmology. He specializes in retinal diseases, with special interests in diabetic retinopathy and macular degeneration. Dr. Bressler's main research interests have been collaborative efforts in clinical trials of common retinal diseases, including age-related macular degeneration and diabetic retinopathy, having chaired several NIH-sponsored and industry-sponsored multicenter randomized clinical trials and authored almost 300 peer-reviewed publications. He is a past chair of the NIH-sponsored Diabetic Retinopathy Clinical Research Network, and was responsible for guidelines, policies, protocol development as well as implementation, and to facilitate Network operations in a way that maintains academic integrity and optimal clinical trial performance. He also has chaired the National Eye Institutes Data and Safety Monitoring Committee for intramural clinical trials and the FDA Ophthalmic Devices Panel. Dr. Bressler is currently editor-in-chief of JAMA Ophthalmology. Dr. Bressler is rated as an Advanced provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal.

Peter L. Gehlbach, M.D., Ph.D. is the J. Willard Marriott, Jr. Professor of Ophthalmology with joint appointment in the Department of Electrical and Computer Engineering, The Whiting School of Engineering. A member of the Wilmer faculty since 2000, he was recruited by a national search to become the inaugural Maumenee Scholar at Johns Hopkins University School of Medicine. His clinical practice is composed of international, national, and regional patient populations with the most complex retinal disease. An expert vitreoretinal surgeon, Dr. Gehlbach has been a leader in performing and teaching complex surgical cases that require coordination with multiple ophthalmological specialists. His research interests include cutting-edge surgical approaches to patients with retinal disease and the development of novel surgical tools and approaches to retinal microsurgery. Dr. Gehlbach’s work has been supported by multiple NIH grants and prestigious foundations with research published in numerous peer-reviewed journals and presented at ophthalmology conferences around the world. The founding director of the former Wilmer Gene Therapy Vector Center, he has served as the director of the Wilmer Echography Center as well as the Retina Fellowship Training Program at Johns Hopkins. He holds multiple patents in both the U.S. and abroad. Dr. Gehlbach received his B.A. and M.D. degrees from the University of Vermont, and his Ph.D. in cell and integrative physiology from the University of Minnesota. He completed an internship and residency training in general surgery at the University of Health Sciences, Chicago Medical School. His ophthalmology residency was at Washington University in St. Louis, where he also completed a fellowship in protein chemistry. He completed a medical and surgical retina fellowship at the Casey Eye Institute in Portland. Dr. Gehlbach is rated as an Advanced provider by MediFind in the treatment of Retinal Vein Occlusion. His top areas of expertise are Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Retinal Detachment, Retinal Vein Occlusion, and Vitrectomy.